Other equities research analysts also recently issued research reports about the stock. Craig Hallum set a $3.00 target price on shares of SenesTech and gave the stock a buy rating in a research report on Wednesday, November 22nd. Zacks Investment Research raised shares of SenesTech from a sell rating to a hold rating in a research report on Thursday, October 12th.
SenesTech (NASDAQ:SNES) traded up $0.06 during mid-day trading on Thursday, reaching $0.66. 324,500 shares of the company’s stock traded hands, compared to its average volume of 160,686. The company has a debt-to-equity ratio of 0.17, a current ratio of 2.94 and a quick ratio of 2.67. SenesTech has a 12-month low of $0.56 and a 12-month high of $10.69.
Several large investors have recently modified their holdings of the company. White Pine Capital LLC acquired a new stake in SenesTech during the second quarter valued at approximately $110,000. Prudential PLC lifted its holdings in shares of SenesTech by 49.3% during the 2nd quarter. Prudential PLC now owns 447,971 shares of the company’s stock worth $2,661,000 after acquiring an additional 147,971 shares during the period. Skylands Capital LLC lifted its holdings in shares of SenesTech by 139.8% during the 3rd quarter. Skylands Capital LLC now owns 87,483 shares of the company’s stock worth $162,000 after acquiring an additional 51,000 shares during the period. TCI Wealth Advisors Inc. bought a new position in shares of SenesTech during the 3rd quarter worth about $748,000. Finally, Gilder Gagnon Howe & Co. LLC lifted its holdings in shares of SenesTech by 3.0% during the 3rd quarter. Gilder Gagnon Howe & Co. LLC now owns 1,078,499 shares of the company’s stock worth $1,995,000 after acquiring an additional 31,330 shares during the period. 14.44% of the stock is owned by institutional investors.
SenesTech, Inc is a United States-based biotechnology platform and research company. The Company is engaged in developing a technology for managing animal populations by fertility control. It offers ContraPest, a fertility control product candidate. ContraPest’s technology and approach targets the reproductive capabilities of both sexes.
Receive News & Ratings for SenesTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SenesTech and related companies with MarketBeat.com's FREE daily email newsletter.